UK will purchase the vaccine from COVID-19 development Sanofi GlaxoSmithKline 500 million pounds
Sanofi and GlaxoSmithKline entered into an agreement with the British government on the delivery of 60 million doses of vaccines against coronavirus 500 million pounds (625 million dollars). We are talking about the experimental vaccine, clinical trials which should begin in September of this year, writes Reuters.
It is expected that the successful completion of clinical trials, vaccine development, Sanofi and GlaxoSmithKline, will be registered in the beginning of next year. Currently, worldwide research is being conducted more than 100 candidate vaccines against coronavirus infection. While there is no approved method for the prevention of coronavirus, however, governments in many countries seek to ensure supplies of vaccines until it is registered, and to obtain performance data.
The agreement with Sanofi and GlaxoSmithKline was not the first for the British government. Earlier, an agreement was reached with Oxford-AstraZeneca about supply of 100 million doses of vaccine of its development.
